Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Randomized, Observer-blind, Placebo-controlled, Multi-center Study to Assess the Prophylactic Efficacy Against Herpes Zoster, Immunogenicity and Safety of Shingrix When Administered Intramuscularly on a 2-dose Schedule in Chinese Adults Aged 50 Years and Older

NCT04869982 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04869982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04869982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Randomized, Observer-blind, Placebo-controlled, Multi-center Study to Assess the Prophylactic Efficacy Against Herpes Zoster, Immunogenicity and Safety of Shingrix When Administered Intramuscularly on a 2-dose Schedule in Chinese Adults Aged 50 Years and Older
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
May 14, 2021
Completion date
April 20, 2023
Enrollment
6,138 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster